Date of Release: July 16, 2019

Expiration Date CME, General CEU's, NSGC, P.A.C.E.®: July 16, 2021

Estimate Time of Completion: Maximum of 21.5 hours

Course must be completed by the expiration date

www.acmgeducation.net

Course Description

The ACMG Genetics and Genomics Review Course offers a 3-day format that provides an intense learning environment with exam preparation lectures that cover a broad range of genetic and genomic topics presented by recognized experts in the field.  Topics include:

•             Cell Biology/Genomics

•             Molecular Biology

•             Laboratory Genetics and Genomics

•             Genetic Transmission

•             Biochemical Genetics

•             Developmental Genetics

•             Cancer Genetics

•             Genetic Counseling & Risk Assessment

•             Newborn Screening

•             Neurogenetics

•             Reproductive Genetics

•             Systems-Based Disorders

•             Genomic Medicine

The Course will feature a pre-course sample examination, exam preparation and exam taking tips, interactive examination workshops with in-depth coverage of exam content areas. There will be an interactive breakout session with faculty on-site.

Learning Objectives

At the conclusion of this activity, participants should be able to:

1.            Identify common genetic syndromes

2.            Discuss the clinical features of common genetic syndromes

3.            Interpret standard molecular data

4.            Explain how to communicate standard molecular data results to families

5.            Perform simple quantitative genetic calculations

6.            Solve simple quantitative genetic calculations related problems

7.            Describe basic cytogenetics

8.            Identify features of common chromosomal disorders

9.            Recognize clinical features of selected metabolic disorders

10.         Describe the molecular basis of selected metabolic disorders

11.         Review how to provide counseling about selected metabolic disorders

12.         Discuss the extents and limits of prenatal tests

13.         Explain how to perform routine prenatal counseling

14.         Explain clinical and molecular aspects of inherited cancer syndromes

15.         Provide genetic counseling for common human cancers

Target Audience

This course is designed to assist genetics healthcare professionals who are seeking to update and reinforce their general knowledge of medical genetics. This course is designed to assist genetics healthcare professionals who are seeking to update and reinforce their general knowledge of medical genetics. This course also allows ABMGG individuals to prepare for Board Certification or Recertification. Genetic counselors are also welcome.

Course Directors

Bruce R. Korf, MD, PhD, FACMG

Wayne H. and Sara Crews Finley Endowed Chair in Medical Genetics

Chief Genomics Officer, UAB Medicine

University of Alabama at Birmingham

1720 2nd Ave. S., Kaul 230

Birmingham, AL 35294

Tel: (205) 934‐9411

E‐mail: bkorf@uab.edu

John A. Phillips, III, MD, FACMG

David T. Karzon Professor of Pediatrics

Professor of Pathology, Microbiology and Immunology and Professor of Medicine

Director, Division of Medical Genetics & Genomic Medicine

Vanderbilt University School of Medicine

DD‐2205 Medical Center North

Nashville, TN 37232‐2578

Tel: (615) 322‐7602

E‐mail: john.a.phillips@vanderbilt.edu

Faculty

Gerard Berry, MD, FACMG

Harvey Levy Chair in Metabolism Director,

Metabolism Program Division of Genetics and Genomics Boston Children’s Hospital

Professor of Pediatrics, Harvard Medical School,

Center for Life Science Building,

3 Blackfan Circle, Suite 14070

Boston, MA 02115

Tel: (617) 355‐4316

E‐mail: Gerard.Berry@childrens.harvard.edu

Pamela L. Flodman, MSc, MS, LCGC

Adjunct Professor, Pediatrics

School of Medicine

Director, Graduate Program in Genetic Counseling

Department of Pediatrics

University of California, Irvine

101 The City Drive

Mail Code: 4482

Orange, CA 92868

Tel: (714) 456‐5789

E‐mail: pflodman@uci.edu

Gary S. Gottesman, MD, FAAP, FACMG

Center for Metabolic Bone Disease and Molecular Research

Shriners Hospitals for Children – St. Louis

4400 Clayton Avenue

St. Louis, MO 63110‐1624

SHC Genomics Institute

2900 North Rocky Point Drive, Tampa, FL 33607

Tel: (314) 872‐8305

E‐mail: ggottesman@shrinenet.org

Elaine Lyon, PhD, FACMG

Director, Clinical Services Laboratory, LLC

HudsonAlpha Institute for Biotechnology

601 Genome Way

Huntsville, AL 35806

email: elyon@hudsonalpha.org

Tel: (256) 327‐9547

Fady M. Mikhail, MD, PhD, FACMG

Co‐Director, Cytogenetics Laboratory

Professor, Department of Genetics, University of Alabama at Birmingham

720 20th Street South, Kaul Genetics Building,

Room #314A

Birmingham, AL 35294

Tel: (205) 934 9588

E‐mail: fmikhail@uab.edu

Sharon E. Plon, MD, PhD, FACMG

Professor, Pediatrics/Hematology‐Oncology

Professor, Molecular and Human Genetics

Human Genome Sequencing Center

Director, Medical Scientist Training Program

Department of Pediatrics

Baylor College of Medicine

Feigin Center Room 1200.18

1102 Bates Street

Houston, TX 77030

Tel: (832) 824‐4251

E‐mail: splon@bcm.edu

Louise E. Wilkins‐Haug, MD, PhD, FACMG

Division Director, Maternal Fetal Medicine and Reproductive Genetics

Brigham & Women's Hospital

Professor, Obstetrics/Gynecology

Harvard Medical School

75 Francis Street

Boston, MA 02115

Tel: (617) 732‐4208

Fax: (617) 264‐6310

E‐mail: Lwilkinshaug@bwh.Harvard.edu

Anthony Wynshaw‐Boris, MD, PhD, FACMG

James H. Jewell Professor of Genetics

Chair, Department of Genetics and Genome

Sciences

Case Western Reserve University, School of

Medicine

University Hospitals Case Medical Center

One 10900 Euclid Avenue, BRB731

Cleveland, OH 44106‐4955

Tel: (216) 368‐0581

E‐mail: ajw168@case.edu

Contributor

Miriam G. Blitzer, PhD, FACMG

Executive Director

American Board of Medical Genetics and Genomics

6120 Executive Boulevard, Suite 525

Rockville, MD 20852

Tel: (301) 634‐7315

E‐mail: mblitzer@abmgg.org or

abmgg@abmgg.org

AGENDA

Thursday, June 27, 2019

Friday, June 28, 2019

Saturday, June 29, 2019

Sunday, June 30, 2019

Financial Disclosures

Disclosure Statement

It is the policy of the American College of Medical Genetics and Genomics to plan and implement all of its educational activities in accordance with the ACCME Essentials and Areas and ACCME® Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Commercial Support, everyone (speakers, moderators, committee members and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all financial relationships with any commercial interests (see definition below) within the past 12 months that creates a real or apparent conflict of interest. Disclosure must include financial relationships of the individual and those of their spouse/partner. Individuals who do not disclose will be disqualified from participating in a CME activity.

This disclosure pertains to relationships with ACCME-defined commercial interests whose products or services may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be managed prior to the educational activity. ACMG will identify, review and resolve all conflicts of interests prior to an educational activity being delivered to learners.

NOTE:

• ACMG will follow the ACCME’s expectation that no employees or owners of commercial interests will be involved as planners/faculty/presenters of a CME accredited activity.
• The ACCME definition of a commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
• The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
• Diagnostic laboratories are not considered commercial interests unless they are owned by or have a sister organization which is a commercial interest.

The following have reported disclosures:

Gerard Berry, MD, FACMG

Dr. Berry is on the Scientific Advisory Board for Genome Medical and Cobalt Biomedicine, Inc. He is a

consultant for Aeglea BioTherapeutics, Inc., Homology Medicines, Inc., Acer Therapeutics, Inc., Hyperion

Therapeutics, Inc. and Biomarin Pharmaceuticals, Inc.

Bruce R. Korf, MD, PhD, FACMG

Dr. Korf is a consultant for SpringWorks and AstraZeneca. He is on the Scientific Advisory Board for

Genome Medical and Envision Genomics. He is on the Board of Directors for the American College of

Medical Genetics and Genomics and the Children’s Tumor Foundation. He is an advisor for the

Neurofibromatosis Therapeutic Acceleration Project, a Founding Member of Envision Genomics. He is

the editor for the American Journal of Human Genetics.

Anthony J. Wynshaw‐Boris, MD, PhD, FACMG

Dr. Wynshaw‐Boris is president‐elect of the American Society of Human Genetics. He is executive editor

of Human Molecular Genetics (Oxford University Press). He is a member of the Advisory Council of the

Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. He is a member of the National

Advisory Child Health and Human Development Council of NICHD.

The following faculty members, staff and contributors have nothing to disclose:

Miriam G. Blitzer, PhD, FACMG

Pamela L. Flodman, MSc, MS, LCGC

Gary S. Gottesman, MD, FAAP, FACMG

Elaine Lyon, PhD, FACMG

Fady M. Mikhail, MD, PhD, FACMG

John A. Phillips, III, MD, FACMG

Sharon Plon, MD, PhD, FACMG

Louise E. Wilkins‐Haug, MD, PhD, FACMG

Jane Radford, MHA, CHCP (ACMG Staff)

educational credit

Continuing Medical Education Credit (CME)

This activity has been planned and implemented by the American College of Medical Genetics and Genomics in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education. 

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Designation

The American College of Medical Genetics and Genomics designates this enduring material for a maximum of 21.5 hours in AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Education Units (Clinical Laboratory Scientists, Directors, and Personnel)
ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program. ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider (50-11878). ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.®. This activity has been approved for a maximum of 21.5 contact hours.

The course ID #20-729756 is registered with CEBroker.

National Society of Genetic Counselors (NSGC).

The National Society of Genetic Counselors (NSGC) has authorized ACMG to offer up to 21.5 CEUs for the activity 2019 ACMG Genetics and Genomics Review Course. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

ACMG will report completed accredited sessions to NSGC for credit certificates on December 4, 2020, and December 3, 2021. Submissions outside of these parameters may incur a processing fee of $35.

Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form.

HIPAA Compliance
The ACMG supports medical information privacy.  While the ACMG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ACMG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ACMG-sponsored events has been properly authorized.  All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information.  If so, they were asked either to attest that a HIPAA-compliant consent form is on file at their institution, or to send ACMG a copy of the ACMG HIPAA compliance form. This information is on record at the ACMG Administrative Office and will be made available on request.

Content Validation
ACMG follows the ACCME policy on Content Validation for CME activities, which requires:

Content Validation and Fair Balance

• ACMG follows the ACCME policy on Content Validation for CME activities, which requires:

1. All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
2. All scientific research referred to, reported or used in CME in support or justification of patient care recommendations must conform to the generally accepted standards of experimental design, data collection and analysis.

2. Activities that fall outside the definition of CME/CE; “Educational activities that serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession” (source: ACCME and AMA) will not be certified for credit. CME activities that promote recommendations, treatment, or manners of practicing medicine or pharmacy that are not within the definition of CME/CE or, are known to have risks or dangers that outweigh the benefits or, are known to be ineffective in the treatment of patients.
3. Presentations and CME/CE activity materials must give a balanced view of therapeutic options; use of generic names will contribute to this impartiality.  If the CME/CE educational materials or content includes trade names, where available, trade names from several companies must be used.

Off-label Uses of Products
When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.

 
Disclaimer
The ACMG does not endorse, or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or test, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.